Our History


  • Promethera Biosciences established Branch Office in Tokyo

  • Promethera Biosciences presents novel data on HepaStem’s Ability to reduce key disease parameters in advanced stage NASH

  • Promethera Biosciences Raised additional EUR 9.3 Million to advance a broad product Pipeline in Severe Liver Diseases

  • Promethera Acquires Baliopharm AG to Strengthen its Therapeutics Strategy in NASH with a unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates


  • Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

  • Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

  • Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

  • Promethera Biosciences Announces Key Additions to its Executive Management Team

  • Promethera Biosciences and LifeLiver Sign Strategic Alliance to Develop Liver Disease Therapeutics in South Korea


  • Promethera Biosciences raised EUR 10 million in a Series C-extension Financing

  • Promethera awarded Pharma Deal of the Year

  • Promethera Biosciences appointed world-class Scientific and Medical Advisory Board

  • Promethera Biosciences appointed New Chairman of the Board of Directors and expansion of the Executive Management Team

  • Promethera Biosciences acquired key assets of Cytonet to create the global leader in regenerative medicine and cell therapy for liver diseases


  • Promethera Biosciences strengthened and completed its management team with two key senior appointments

  • Promethera Biosciences appoints Dr John Tchelingerian as CEO

  • Promethera Biosciences opened "Plateforme Wallonne de Thérapie Cellulaire"


  • From Phase I/II to next clinical trial manufacturing: from open to a closed system using ATMI’s XP bioreactor technology

  • Promethera Biosciences partner with EMD Millipore to deliver a pre-clinical liver pharmaco-toxicological testing assay

  • Promethera Biosciences appoint Frank Hazevoets as chief financial officer

  • Promethera Biosciences receives approval in Belgium to enrol patients in the Phase IIb/III (HEP002) clinical trial

  • Promethera Biosciences Series C financial round - €25.33 million ($31.4 million)


  • Phase I/II: Promethera Biosciences opened the French part of its clinical trial in cell therapy

  • Phase I/II: Promethera Biosciences opened the United Kingdom part of its clinical trial in cell therapy

  • Phase I/II: Promethera Biosciences opened the Italian part of its clinical trial in cell therapy

  • Phase I/II: Promethera Biosciences successfully enrols twenty patients in its multicentric Phase I/II trial


  • Belgian Authorities granted GMP accreditation of the manufacturing facility located in Mont-Saint-Guibert

  • Belgian authorities (AFMPS) and British authorities (MHRA) approved HepaStem Phase I/II clinical trial involving Crigler Najjar and Urea Cycle Disorders patients

  • Promethera Biosciences raised EUR 23.6 million (~ USD 31.4 million) in Series-B financing round in March 2012

  • Promethera develops of a mobile unit for the formulation and distribution of HepaStem

  • Phase I/II: Promethera Biosciences treated first patients with Promethera HepaStem


  • Patent granted by the European Patent Office

  • Successful technology transfer of manufacturing process from UCL into Promethera’s large scale facility

  • Pre-clinical proof of concept in three different models

  • World first proof of concept in man - treating three patients with HHALPCs


  • Company Foundation

Sign Up